Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction ...

In a recent study published in Jama Network, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF). Study: Viral Antigen and ...

Cerebrospinal fluid (CSF) and other biomarkers differ for individuals with Alzheimer disease and cognitively normal controls, with the estimated times of divergence varying from 18 to six years before ...

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...

GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia CRISPR/Cas9-Mediated GM-CSF knock-out (GM-CSF ko) CAR-T cells demonstrate reduced apoptosis and enhanced in vivo anti-tumor ...

Researchers from the MPI of Biochemistry and the Technical University of Munich have discovered new diagnostic markers for multiple sclerosis (MS), a disease that affects 3 million people worldwide.

ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma.

A study published in the Journal of Cannabis Research examined the effect of granulocyte colony-stimulating factor (G-CSF) on brain recovery following traumatic brain injury (TBI). The findings showed ...